我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

冠状动脉粥样斑块的治疗现状与进展(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第2期
页码:
224-227
栏目:
综述
出版日期:
2016-11-25

文章信息/Info

Title:
Progress of non-surgical treatments of coronary atherosclerotic plaque
作者:
何浩辉 综述; 郭 军 审校
（暨南大学附属第一医院心血管内科，广东 广州 510630）
Author(s):
HE Hao-hui;  GUO Jun
(Department of Cardiology, First Affiliated Hospital, Jinan University, Guangzhou 510630, Guangdong, China)
关键词:
粥样斑块; 药物治疗; 内皮祖细胞; 生活方式干预
Keywords:
atherosclerotic plaque;  drug therapy;  endothelial progenitor cells;  lifestyle intervention
分类号:
R543.31
DOI:
-
文献标识码:
A
摘要:
冠状动脉粥样斑块是冠状动脉粥样硬化性心脏病的基本病理改变，斑块的破裂可以导致急性冠脉综合征。如何干预动脉粥样斑块是目前的研究热点，大量研究已证实，药物治疗、内皮祖细胞移植、生活方式干预等方法可以早期干预动脉粥样斑块。本文将从以上方面介绍冠状动脉粥样斑块的治疗方法研究现状及相关机制。
Abstract:
Coronary plaque is the basic pathological change of coronary heart disease. Acute coronary syndrome occurs after plaque rupture. Current research mainly focuses on atherosclerotic plaque intervention and many studies have proven that non-surgical treatments such as drugs, endothelial progenitor cell transplantation, and lifestyle intervention can reduce coronary atherosclerotic plaque in early stages. This article introduces the progress in non-surgical treatments and mechanisms of coronary atherosclerotic plaque.

参考文献/References

[1]Niessner A,Goronzy JJ,Weyand CM.Immune-mediated mechanisms in atherosclerosis:prevention and treatment of clinical manifestations[J].Curr Pharm Des,2007,13(36):3701-3710.
[2]Nissen SE,Nicholls SJ,Sipahi I,et al.Effect of very high intensity statin therapy on regression of coronary atherosclerosis:The ASTEROID trial[J].JAMA,2006,295(13):1556-1565.
[3]Takayama T,Hiro T,Yamaqishi M,et al.Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjecrs (COSMOS)[J].Circ J,2009,73(11):2110-2117.
[4]Nissen SE,Tuzcu EM,Schoenhagen P,et al.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial[J].JAMA,2004,291(9):1071-1080.
[5]白赟,叶丽平,高远生.热休克蛋白在动脉粥样硬化发生发展中作用的研究进展[J].生理科学进展,2014,45(1):1-6.
[6]Moohebati M,Bidmeshqi S,Azarpazhooh MR,et al.Simvastatin trearment reduces heat shock protein 60,65,and 70 antibody titers in dyslipidemic patients: A randomized, double-blind,placebo-controlled,cross-over trial[J].Clin Biochem,2011,44(2-3):192-197.
[7]Puri R,Nicholls SJ,Shao M,et al.Impact of statins on serial coronary calcification during atheroma progression and regression[J].J Am Coll Cardiol,2015,65(13):1273-1282.
[8]骆莹莹,陈 述,王大新.氧化应激对动脉粥样硬化内皮细胞损伤作用的研究进展[J].医学综述,2015,21(5):772-775.
[9]董红梅,黄 岚,宋耀明,等.普鲁布考对急性冠脉综合征患者血浆ox-LDL、炎症因子的干预效应[J].心脏杂志,2007,19(4):434-437.
[10]Barnhart RL,Busch SJ,Jackson RL.Concentration-dependent antioxidant activity of probucol in low density lopoproteins in vitro:probucol degradation precedes lipoprotein oxidation[J].J Lipid Res,1989,30(11):1703-1710.
[11]Yi GH,Mo ZC,Ye YP,et al.Effects of probucol on paraoxonase 1 expression and oxidative strees in hyperlipidemic mice[J].Cell Biol Int,2008,32(3):S19-S20.
[12]Umeji K,Umemoto S,Itoh S,et al.Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase PPAR-gamma, and aortic stiffness in hypercholesterolemia[J].Am J Phusiol Heart Cric Physiol,2006,291(5):H2522-H2532.
[13]Suqizaki T,Watanabe M,Harai Y,et al.The niemann-pick C1 like 1(NPC1L1)inhibitor ezetimibe improve metabolic disease via decreased liver X receptor(LXR)activity in liver of obese male mice[J].Endocrinology,2014,155(8):2810-2819.
[14]Roeters van Lennep HW,Liem AH,Dunselman PH,et al.The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin:results of the EASEGO study[J].Curr Med Opin,2008,24(3):685-694.
[15]Moutzouri E,Liberopoulos EN,Tellis CC,et al.Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia[J]. Atherosclerosis,2013,231(1):8-14.
[16]M?ki-Pet?j? KM,Booth AD,Hall FC,et al.Ezetimibe and simvastatin reduce inflammation,disease activity,and aortic stiffness and improve endothelial function in rheumatoid arthritis[J].J Am Coll Cardiol,2007,50(9):852-858.
[17]Chu NN,Chen WL,Xu HR,et al.Pharrmacokinetics and safety of ezetimibe/simvascular combinatin tablet:an open-label, single-does study in healthy Chinese subjects[J].Clin Drug Ivestig,2012,32(12):791-798.
[18]Petit I,Jin D,Rafli S.The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis[J].Trends Immunol,2007,28(7):299-307.
[19]Yao L,Heuser-Baker J,Herlea-Pana O,et al.Bone marrow endothelial progenitors augment atherosclerotic plaque regression in a mouse model of plasma lipid lowering[J].Stem Cells,2012,30(12):2720-2731.
[20]Tousoulis D,Briasoulis A,Vogiatzi G,et al.Effects of direct infusion of bone marrow-derived progenitor cells and indirect mobilization of hematopoietic progenitor cells on atherosclerotic plaque and inflammatory process in atherosclerosis[J].Int J Cardiol,2013,168(5):4769-4774.
[21]张丽洁,吕树铮.易损斑块与内皮祖细胞研究进展[J].心血管病学进展,2008,29(6):854-857.
[22]Alex Y,Ozaki Y,Kasuya J,et al.Endothelial progenitor cells promote directional three-dimensional endothelial network formation by screening vascular endothelial growth factor[J].PLoS One,2013,8(12):e82085.
[23]Lambiase PD,Edwards RJ,Anthopoulos P,et al.Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support[J].Circulation,2004,109(24):2986-2992.
[24]Hellings WE,Wouter P,Moll FL,et al.Composition of carotid atherosclerotic plaque is asscociated with cardiovascular outcome: a prognostic study[J].Circulation,2010,121(17):1941-1950.
[25]George J,Afek A,Abashidze A,et al.Transfer of endotjelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apoliprotein E knockout mice[J].Arterioscler Thromb Vasc Biol,2005,25(12):2636-2641.
[26]Watts GF,Lewis JN,Brunt JN,et al.Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas'Atherosclerosis Regression Study(STARS)[J].Lancet,1992,339(8793):563-569.
[27]Haskell WL,Alderman EL,Fair JM,et al.Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project(SCRIP)[J].Circulation,1994,89(3):975-990.
[28]Schuler G,Hambrecht R,Schlierf G,et al.Regular physical exercise and low-fat diet.Effects on progression of coronary artery disease[J].Circulation,1992,86(1):1-11.
[29]Tsai TH,Chai HT,Sun CK,et al.Obesity suppresses circulating level and function of endothelial progenitor cells and heart function[J].J Transl Med,2012,10:137.
[30]De Biase C,De Rosa R,Luciano R,et al.Effects of physical activity on endothelial progenitor cells (EPCs)[J].Front Physiol,2014,4:414.

备注/Memo

备注/Memo:
收稿日期：2015-11-25.
基金项目：国家自然科学基金青年项目资助（81100078）；教育部科学研究重点项目资助（211207）；广州珠江科技新星资助计划项目资助（2012J2200063）；广东省科技厅博士启动项目资助（S2011040001392）；暨南大学科研培育与创新基金-医学联合基金项目资助（21615478）
通讯作者：郭军，副主任医师，主要从事心血管病学研究 Email:dr.guojun@163.com
作者简介：何浩辉，硕士生 Email:1051095870@qq.com
更新日期/Last Update: 2016-10-11